

(FILE 'HOME' ENTERED AT 20:15:20 ON 25 JUL 2003)

FILE 'CAPLUS' ENTERED AT 20:15:29 ON 25 JUL 2003

L1 1 S US5436240/PN  
S 5273975/CN

FILE 'REGISTRY' ENTERED AT 20:15:51 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:15:52 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:16:04 ON 25 JUL 2003

L7 1 S US5273975/PN  
SELECT L1 1 RN  
SELECT L7 1 RN

FILE 'REGISTRY' ENTERED AT 20:21:53 ON 25 JUL 2003

L8 STRUCTURE UPLOADED  
L9 143 S L8 SSS FULL

FILE 'CAPLUS' ENTERED AT 20:22:22 ON 25 JUL 2003

L10 50 S L9  
L11 22 S E219-225 OR E234-398  
L12 12 S L10 AND L11  
L13 33474 S L12 AND ADDICTIVE? OR ADDIC? OR INTOXIC?  
L14 0 S L12 AND (ADDICTIVE? OR ADDIC? OR INTOXIC?)  
SAVE ALL L09929666/L  
SAVE L11 A09929666/A  
L15 1 S QUINAZOL? AND (ADDICTIVE)

FILE 'USPATFULL' ENTERED AT 20:56:19 ON 25 JUL 2003

L16 58 S QUINAZOL? AND (ADDICTIVE)  
L17 0 S L11  
L18 25 S L9  
L19 2 S L18 AND (ADDICTIVE)  
L20 0 S E16-E183  
L21 1 S US5436240/PN  
SELECT L21 1 RN  
L22 9992 S E437-616  
L23 58 S L22 AND (ADDICTIVE)

FILE 'REGISTRY' ENTERED AT 21:06:38 ON 25 JUL 2003

L24 STRUCTURE UPLOADED  
L25 51 S L24 SSS FULL

FILE 'USPATFULL' ENTERED AT 21:06:57 ON 25 JUL 2003

L26 3 S L25  
L27 0 S L16 AND L26  
L28 444 S IMIDAZO (5A) QUINOL?  
L29 2 S L28 AND (ADDICTIVE)

FILE 'REGISTRY' ENTERED AT 21:10:12 ON 25 JUL 2003

FILE 'USPATFULL' ENTERED AT 21:10:13 ON 25 JUL 2003

FILE 'REGISTRY' ENTERED AT 21:13:01 ON 25 JUL 2003

L30 STRUCTURE UPLOADED  
L31 56 S L30 SSS FULL

FILE 'CAPLUS, USPATFULL' ENTERED AT 21:13:55 ON 25 JUL 2003

L32 19 FILE CAPLUS  
L33 3 FILE USPATFULL


TOTAL FOR ALL FILES

L34 22 S L31  
 L35 0 FILE CAPLUS  
 L36 0 FILE USPATFULL  
 TOTAL FOR ALL FILES  
 L37 0 S L34 AND ADDICT?  
 L38 STRUCTURE UPLOADED  
  
 FILE 'REGISTRY' ENTERED AT 21:15:52 ON 25 JUL 2003  
 L39 145604 FILE USPATFULL  
  
 FILE 'CAPLUS, USPATFULL' ENTERED AT 21:16:07 ON 25 JUL 2003  
 L40 13 FILE CAPLUS  
 L41 377 FILE CAPLUS  
 L42 STRUCTURE UPLOADED  
  
 FILE 'REGISTRY' ENTERED AT 21:24:29 ON 25 JUL 2003  
 L43 STRUCTURE UPLOADED  
 L44 0 FILE USPATFULL  
 L45 STRUCTURE UPLOADED  
 L46 6296 S L45 SSS FULL  
  
 FILE 'CAPLUS' ENTERED AT 21:25:40 ON 25 JUL 2003  
 L47 1860 S L46  
 L48 172 S L47 AND (ADDICTIVE OR (PSYCHOACTIVE SUBSTANCE) OR TOBACCO OR  
 L49 1 S L47 AND ADDICTION

FILE 'REGISTRY' ENTERED AT 21:33:40 ON 25 JUL 2003

=> d l31

L31 ANSWER 1 OF 56 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 369594-66-1 REGISTRY  
 CN 1H,5H-Pyrido[3,2,1-ij]quinazoline-1,3(2H)-dione, 6-amino-6,7-dihydro-,  
 monohydrochloride (9CI) (CA INDEX NAME)  
 MF C11 H11 N3 O2 . Cl H  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



● HCl

1 REFERENCES IN FILE CA (1947 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1947 TO DATE).

=> d l8  
 L8 HAS NO ANSWERS  
 L8 STR

(FILE 'HOME' ENTERED AT 20:15:20 ON 25 JUL 2003)

FILE 'CAPLUS' ENTERED AT 20:15:29 ON 25 JUL 2003

L1           1 S US5436240/PN  
              S 5273975/CN

FILE 'REGISTRY' ENTERED AT 20:15:51 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:15:52 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:16:04 ON 25 JUL 2003

L7           1 S US5273975/PN  
              SELECT L1 1 RN  
              SELECT L7 1 RN

FILE 'REGISTRY' ENTERED AT 20:21:53 ON 25 JUL 2003

L8           STRUCTURE UPLOADED  
L9           143 S L8 SSS FULL

FILE 'CAPLUS' ENTERED AT 20:22:22 ON 25 JUL 2003

L10          50 S L9  
L11          22 S E219-225 OR E234-398  
L12          12 S L10 AND L11  
L13          33474 S L12 AND ADDICTIVE? OR ADDIC? OR INTOXIC?  
L14          0 S L12 AND (ADDICTIVE? OR ADDIC? OR INTOXIC?)  
              SAVE ALL L09929666/L  
              SAVE L11 A09929666/A

=>

L19 ANSWER 2 OF 2 USPATFULL on STN

TI Compounds for the treatment of **addictive disorders**

AB The treatment of **addictive disorders**, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described herein.

SUMM [0002] The invention relates to the use of neuromuscular agents, and the pharmacologically acceptable salts thereof, for the treatment of, or improving symptoms of, several nervous system disorders. More particularly, the invention relates to treatment and improvement of symptoms related to **addictive disorders**, psychoactive substance use disorders, nicotine addiction, and tobacco addiction.

SUMM [0008] More recently, scientists have considered whether these compounds having useful properties for treating neuromuscular disorders can be used for treating other nervous system disorders, particularly **addictive diseases**. More particularly, the use of these compounds for nervous systems disorders, for example, **addictive disorders**, psychoactive substance use disorders, nicotine addiction, or tobacco addiction resulting in smoking cessation, have been considered.

SUMM [0009] In addition to the previously mentioned compounds, aromatic bicyclic amine compounds have also been investigated for potential activity useful for treating nervous system disorders, such as **addictive diseases**. The aromatic bicyclic amine compounds have been reported to demonstrate activity useful for treatment of some central nervous system disorders, for example, schizophrenia, and cardiovascular disease, such as cardiac arrhythmias and cardiac fibrillation. Bicyclic amine compounds and methods of making the same are described in U.S. Pat. No. 5,877,317, issued Mar 2, 1999.

SUMM [0010] Methods for using the described compounds for treating **addictive-type** nervous disorders has not been reported. Methods and dosages for using heterocyclic amine compounds, phenylazacycloalkane compounds, cabergoline, aromatic bicyclic amine compounds and the derivatives of these classes of compounds for treating specific **addictive disorders** are described herein.

SUMM [0011] The invention provides a method for the treatment of certain **addictive disorders**, for example, psychoactive substance use disorders, nicotine addiction or tobacco addiction (with a result of smoking cessation or a decrease in smoking). The method includes the step of administering a therapeutically effective, nontoxic dose of a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine compound, or a pharmaceutically acceptable salt or derivative thereof, to a patient suffering from or susceptible to such an addiction or disorder.

DETD [0012] Heterocyclic amine, phenylazacycloalkane, cabergoline, aromatic bicyclic amine compounds, and the pharmaceutically acceptable salts or derivatives of these compounds can be used to treat and ameliorate nervous system disorders. The disorders typically can include, but are not limited to, **addictive disorders**, psychoactive substance use disorders, nicotine addiction, tobacco addiction, and other diseases or disorders related to affliction of the nervous system, and more particularly, the central nervous system.

DETD [0013] Several compounds demonstrating activity in treating neuromuscular disease have been identified for the method of the invention. The following classes of compounds can be used for treating or suppressing the symptoms of conditions related to nervous system

affliction, particularly **addictive** disorders. Examples of at least the following classes of compounds are provided for the method of the invention.

DETD [0118] For treating the **addictive** disorders described herein the drug may also be provided in chewable format, such as a chewing gum. The amount of active drug included in a chewable base may be half the dosage suggested above for the tablet, for example starting with about 0.075 mg of cabergoline per square of chewing gum being administered tid and followed with higher levels after the patient shows tolerance to the drug. Chewing gum dosages contemplated within the scope of the invention include at least 0.075, 0.10, 0.125, 0.150 mg/day, in addition to those mentioned for a tablet for heterocyclic amine compounds, phenylazacycloalkane compounds, and cabergoline or cabergoline-type compounds. Similarly, dosages contemplated for the aromatic bicyclic amine compounds include from about 2.5 mg/day to about 125 mg/day. One or two chewing gum squares can be provided to the patient up to three times a day, depending on the therapeutic need of the recipient.

DETD [0123] **Addictive** disorders and psychoactive substance use disorders, such as intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and/or nicotine addiction can be treated according to the invention. Tobacco and nicotine addiction would be treated with the goal of achieving either smoking cessation or at least a reduction in the intake of tobacco and/or nicotine. General descriptions of **addictive** disorders, including disorders related to intoxication, inhalants, and tobacco addiction or nicotine addiction can be found in many standard sources. The addictions and behaviors that can be treated by the invention generally are further described in, for example, The American Psychiatric Press Textbook of Psychiatry, Second Edition, edited by Robert E. Hales, Stuart C. Yudofsky, and John A. Talbott, 1994, incorporated by reference, especially pp. 401 et. seq., section on "Nicotine" incorporated by reference; and Manual of Psychiatric Therapeutics, Second Edition, edited by Richard I. Shader, incorporated by reference, especially pp. 85 from Chapter 11, entitled "Hypnosis".

CLM What is claimed is:

1. A method of treating or suppressing the symptoms of at least one disorder selected from **addictive** disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction, said method comprising the step of administering a therapeutically effective, nontoxic amount of an active agent selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, a cabergoline, an aromatic bicyclic amine, and pharmaceutically acceptable derivatives or salts of any said active agent, to a patient in need of treatment.

IT 81409-90-7, Cabergoline 156907-84-5 170858-36-3 170858-41-0  
173590-06-2 179386-43-7 282522-93-4  
282522-94-5 369595-93-7 400716-28-1 400716-30-5  
400716-32-7

(compds. for the treatment of addictive disorders)

ACCESSION NUMBER: 2002:92682 USPATFULL


TITLE: Compounds for the treatment of **addictive** disorders

INVENTOR(S): Anderson, Richard W., Annandale, NJ, UNITED STATES  
McBrinn, Sylvia S., Stockton, NJ, UNITED STATES  
Robertson, David W., Galesburg, MI, UNITED STATES  
Marshall, Robert C., Mattawan, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002049206	A1	20020425
APPLICATION INFO.:	US 2001-929666	A1	20010814 (9)


	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-263610P	20010123 (60)
	US 2000-225714P	20000816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER DRIVE, CHICAGO, IL, 60606-6402	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	830	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT 179386-43-7 282522-93-4 282522-94-5		
(compds. for the treatment of addictive disorders)		
RN	179386-43-7 USPATFULL	
CN	4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry. Rotation (-).



RN	282522-93-4 USPATFULL	
CN	4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.




RN	282522-94-5 USPATFULL	
CN	4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)	

CM 1

CRN 282522-93-4  
CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z

Double bond geometry as shown.



L19 ANSWER 1 OF 2 USPATFULL on STN

TI Compounds for the treatment of **addictive** disorders

AB The treatment of **addictive** disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described herein.

SUMM [0002] The invention relates to the use of neuromuscular agents, and the pharmacologically acceptable salts thereof, for the treatment of, or improving symptoms of, several nervous system disorders. More particularly, the invention relates to treatment and improvement of symptoms related to **addictive** disorders, psychoactive substance use disorders, nicotine addiction, and tobacco addiction.

SUMM [0008] More recently, scientists have considered whether these compounds having useful properties for treating neuromuscular disorders can be used for treating other nervous system disorders, particularly **addictive** diseases. More particularly, the use of these compounds for nervous systems disorders, for example, **addictive** disorders, psychoactive substance use disorders, nicotine addiction, or tobacco addiction resulting in smoking cessation, have been considered.

SUMM [0009] In addition to the previously mentioned compounds, aromatic bicyclic amine compounds have also been investigated for potential activity useful for treating nervous system disorders, such as **addictive** diseases. The aromatic bicyclic amine compounds have been reported to demonstrate activity useful for treatment of some central nervous system disorders, for example, schizophrenia, and cardiovascular disease, such as cardiac arrhythmias and cardiac fibrillation. Bicyclic amine compounds and methods of making the same are described in U.S. Pat. No. 5,877,317, issued Mar. 2, 1999.

SUMM [0010] Methods for using the described compounds for treating **addictive**-type nervous disorders has not been reported. Methods and dosages for using heterocyclic amine compounds, phenylazacycloalkane compounds, cabergoline, aromatic bicyclic amine compounds and the derivatives of these classes of compounds for treating specific **addictive** disorders are described herein.

SUMM [0011] The invention provides a method for the treatment of certain **addictive** disorders, for example, psychoactive substance use disorders, nicotine addiction or tobacco addiction (with a result of smoking cessation or a decrease in smoking). The method includes the step of administering a therapeutically effective, nontoxic dose of a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine compound, or a pharmaceutically acceptable salt or derivative thereof, to a patient suffering from or susceptible to such an addiction or disorder.

DETD [0012] Heterocyclic amine, phenylazacycloalkane, cabergoline, aromatic bicyclic amine compounds, and the pharmaceutically acceptable salts or derivatives of these compounds can be used to treat and ameliorate nervous system disorders. The disorders typically can include, but are not limited to, **addictive** disorders, psychoactive substance use disorders, nicotine addiction, tobacco addiction, and other diseases or disorders related to affliction of the nervous system, and more particularly, the central nervous system.

DETD [0013] Several compounds demonstrating activity in treating neuromuscular disease have been identified for the method of the invention. The following classes of compounds can be used for treating or suppressing the symptoms of conditions related to nervous system affliction, particularly **addictive** disorders. Examples of at



least the following classes of compounds are provided for the method of the invention.

DETD [0122] For treating the **addictive** disorders described herein the drug may also be provided in chewable format, such as a chewing gum. The amount of active drug included in a chewable base may be half the dosage suggested above for the tablet, for example starting with about 0.075 mg of cabergoline per square of chewing gum being administered tid and followed with higher levels after the patient shows tolerance to the drug. Chewing gum dosages contemplated within the scope of the invention include at least 0.075, 0.10, 0.125, 0.150 mg/day, in addition to those mentioned for a tablet for heterocyclic amine compounds, phenylazacycloalkane compounds, and cabergoline or cabergoline-type compounds. Similarly, dosages contemplated for the aromatic bicyclic amine compounds include from about 2.5 mg/day to about 125 mg/day. One or two chewing gum squares can be provided to the patient up to three times a day, depending on the therapeutic need of the recipient.

DETD [0127] **Addictive** disorders and psychoactive substance use disorders, such as intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and/or nicotine addiction can be treated according to the invention. Tobacco and nicotine addiction would be treated with the goal of achieving either smoking cessation or at least a reduction in the intake of tobacco and/or nicotine. General descriptions of **addictive** disorders, including disorders related to intoxication, inhalants, and tobacco addiction or nicotine addiction can be found in many standard sources. The addictions and behaviors that can be treated by the invention generally are further described in, for example, The American Psychiatric Press Textbook of Psychiatry, Second Edition, edited by Robert E. Hales, Stuart C. Yudofsky, and John A. Talbott, 1994, incorporated by reference, especially pp. 401 et. seq., section on "Nicotine" incorporated by reference; and Manual of Psychiatric Therapeutics, Second Edition, edited by Richard I. Shader, incorporated by reference, especially pp. 85 from Chapter 11, entitled "Hypnosis".

CLM What is claimed is:

1. A method of treating or suppressing the symptoms of at least one disorder selected from **addictive** disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction, said method comprising the step of administering a therapeutically effective, nontoxic amount of an active agent selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, a cabergoline, an aromatic bicyclic amine, and pharmaceutically acceptable derivatives or salts of any said active agent, to a patient in need of treatment.

IT 81409-90-7, Cabergoline 156907-84-5 170858-36-3 170858-41-0  
173590-06-2 179386-43-7 282522-93-4  
282522-94-5 369595-93-7 400716-28-1 400716-30-5  
400716-32-7

(compds. for the treatment of addictive disorders)

ACCESSION NUMBER: 2003:113532 USPATFULL


TITLE: Compounds for the treatment of **addictive** disorders

INVENTOR(S): Anderson, Richard W., Annandale, NJ, UNITED STATES  
McBrinn, Sylvia S., Stockton, NJ, UNITED STATES  
Robertson, David W., Galesburg, MI, UNITED STATES  
Marshall, Robert C., Mattawan, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078273	A1	20030424
APPLICATION INFO.:	US 2002-295331	A1	20021115 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-929666, filed on 14 Aug 2001, PENDING		


	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-263610P	20010123 (60)
	US 2000-225714P	20000816 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	831	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
IT	179386-43-7 282522-93-4 282522-94-5	
	(compds. for the treatment of addictive disorders)	
RN	179386-43-7 USPATFULL	
CN	4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R) - (9CI) (CA INDEX NAME)	

Absolute stereochemistry. Rotation (-).



RN 282522-93-4 USPATFULL  
 CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282522-94-5 USPATFULL  
 CN 4H-Imidazo[4,5,1-ij]quinoline-2(1H)-thione, 5,6-dihydro-5-(methylamino)-, (5R) -, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 282522-93-4  
 CMF C11 H13 N3 S

Absolute stereochemistry.




CM 2


CRN 110-16-7

CMF C4 H4 O4

CDES 2:Z


Double bond geometry as shown.





Structure attributes must be viewed using STN Express query preparation.


=> d 124  
L24 HAS NO ANSWERS  
L24 STR



G1 C,S,N  
G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.


=> d 130  
L30 HAS NO ANSWERS  
L30 STR



G1 C,S,N  
G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> d 138  
L38 HAS NO ANSWERS  
L38 STR



G1 C,S,N


G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> d 142

L42 HAS NO ANSWERS

L42 STR



G1 C,S,N

G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=>

(FILE 'HOME' ENTERED AT 20:15:20 ON 25 JUL 2003)

FILE 'CAPLUS' ENTERED AT 20:15:29 ON 25 JUL 2003  
L1 1 S US5436240/PN  
S 5273975/CN

FILE 'REGISTRY' ENTERED AT 20:15:51 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:15:52 ON 25 JUL 2003

FILE 'CAPLUS' ENTERED AT 20:16:04 ON 25 JUL 2003  
L7 1 S US5273975/PN  
SELECT L1 1 RN  
SELECT L7 1 RN

FILE 'REGISTRY' ENTERED AT 20:21:53 ON 25 JUL 2003  
L8 STRUCTURE UPLOADED  
L9 143 S L8 SSS FULL

FILE 'CAPLUS' ENTERED AT 20:22:22 ON 25 JUL 2003  
L10 50 S L9  
L11 22 S E219-225 OR E234-398  
L12 12 S L10 AND L11  
L13 33474 S L12 AND ADDICTIVE? OR ADDIC? OR INTOXIC?  
L14 0 S L12 AND (ADDICTIVE? OR ADDIC? OR INTOXIC?)  
SAVE ALL L09929666/L  
SAVE L11 A09929666/A  
L15 1 S QUINAZOL? AND (ADDICTIVE)

FILE 'USPATFULL' ENTERED AT 20:56:19 ON 25 JUL 2003  
L16 58 S QUINAZOL? AND (ADDICTIVE)  
L17 0 S L11  
L18 25 S L9  
L19 2 S L18 AND (ADDICTIVE)  
L20 0 S E16-E183  
L21 1 S US5436240/PN  
SELECT L21 1 RN  
L22 9992 S E437-616  
L23 58 S L22 AND (ADDICTIVE)

FILE 'REGISTRY' ENTERED AT 21:06:38 ON 25 JUL 2003  
L24 STRUCTURE UPLOADED  
L25 51 S L24 SSS FULL

FILE 'USPATFULL' ENTERED AT 21:06:57 ON 25 JUL 2003  
L26 3 S L25  
L27 0 S L16 AND L26  
L28 444 S IMIDAZO (5A) QUINOL?  
L29 2 S L28 AND (ADDICTIVE)


FILE 'REGISTRY' ENTERED AT 21:10:12 ON 25 JUL 2003

FILE 'USPATFULL' ENTERED AT 21:10:13 ON 25 JUL 2003

FILE 'REGISTRY' ENTERED AT 21:13:01 ON 25 JUL 2003  
L30 STRUCTURE UPLOADED  
L31 56 S L30 SSS FULL

FILE 'CAPLUS, USPATFULL' ENTERED AT 21:13:55 ON 25 JUL 2003  
L32 19 FILE CAPLUS  
L33 3 FILE USPATFULL  
TOTAL FOR ALL FILES  
L34 22 S L31


L35 0 FILE CAPLUS  
 L36 0 FILE USPATFULL  
 TOTAL FOR ALL FILES  
 L37 0 S L34 AND ADDICT?  
 L38 STRUCTURE UPLOADED  
  
 FILE 'REGISTRY' ENTERED AT 21:15:52 ON 25 JUL 2003  
 L39 145604 FILE USPATFULL  
  
 FILE 'CAPLUS, USPATFULL' ENTERED AT 21:16:07 ON 25 JUL 2003  
 L40 13 FILE CAPLUS  
 L41 377 FILE CAPLUS  
 L42 STRUCTURE UPLOADED  
  
 FILE 'REGISTRY' ENTERED AT 21:24:29 ON 25 JUL 2003  
 L43 STRUCTURE UPLOADED  
 L44 0 FILE USPATFULL  
 L45 STRUCTURE UPLOADED  
 L46 6296 S L45 SSS FULL  
  
 FILE 'CAPLUS' ENTERED AT 21:25:40 ON 25 JUL 2003  
 L47 1860 S L46  
 L48 172 S L47 AND (ADDICTIVE OR (PSYCHOACTIVE SUBSTANCE) OR TOBACCO OR  
 L49 1 S L47 AND ADDICTION  
  
 FILE 'REGISTRY' ENTERED AT 21:33:40 ON 25 JUL 2003  
  
 => d 131  
  
 L31 ANSWER 1 OF 56 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 369594-66-1 REGISTRY  
 CN 1H,5H-Pyrido[3,2,1-ij]quinazoline-1,3(2H)-dione, 6-amino-6,7-dihydro-,  
 monohydrochloride (9CI) (CA INDEX NAME)  
 MF C11 H11 N3 O2 . Cl H  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



● HCl

1 REFERENCES IN FILE CA (1947 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1947 TO DATE)

=> d 18  
 L8 HAS NO ANSWERS  
 L8 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 124

L24 HAS NO ANSWERS

L24 STR



G1 C,S,N


G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> d 130

L30 HAS NO ANSWERS

L30 STR



G1 C,S,N

G2 C,O,N


Structure attributes must be viewed using STN Express query preparation.

=> d 138

L38 HAS NO ANSWERS

L38 STR





G1 C,S,N


G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> d 142

L42 HAS NO ANSWERS

L42 STR



G1 C,S,N

G2 C,O,N

Structure attributes must be viewed using STN Express query preparation.

=> save all

ENTER NAME OR (END):109929666/1

'L09929666/L' IN USE

A single name cannot be used for two saved items at the same time.  
Enter "Y" if you wish to replace the current saved name with a new definition. Enter "N" if the current saved definition must be preserved. You may then reenter the SAVE command with a different saved name. Enter "DISPLAY SAVED" at an arrow prompt (=>) to see a list of your currently defined saved names.


REPLACE OLD DEFINITION? Y/(N):y

L# LIST L1-L49 HAS BEEN SAVED AS 'L09929666/L'

=>

RN 132874-72-7 CAPLUS

CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5-(dipropylamino)-5,6-dihydro-,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl